Compare ARKO & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARKO | SLDB |
|---|---|---|
| Founded | 1970 | 2013 |
| Country | United States | United States |
| Employees | 9748 | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 608.8M | 498.6M |
| IPO Year | N/A | 2017 |
| Metric | ARKO | SLDB |
|---|---|---|
| Price | $5.69 | $8.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $7.50 | ★ $16.36 |
| AVG Volume (30 Days) | 999.8K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,094,000.00 |
| Revenue This Year | $12.86 | N/A |
| Revenue Next Year | $1.49 | N/A |
| P/E Ratio | $56.88 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.71 | $2.45 |
| 52 Week High | $6.71 | $8.69 |
| Indicator | ARKO | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 53.55 | 61.59 |
| Support Level | $4.80 | $5.16 |
| Resistance Level | $6.65 | $8.47 |
| Average True Range (ATR) | 0.23 | 0.63 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 61.03 | 77.04 |
ARKO Corp owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in four segments: Retail segment, Wholesale segment, fleet fueling segment, and GPM Petroleum segment. It derives the majority of its revenue from retail and wholesale distribution of fuel.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.